Walden Biosciences teams up with Primula for kidney disease study
Walden reported positive topline data from a Phase I clinical trial of its lead candidate WAL0921, a humanised mAb to treat kidney disease.
Walden reported positive topline data from a Phase I clinical trial of its lead candidate WAL0921, a humanised mAb to treat kidney disease.
What's Your Reaction?
